By Sheeba M. | April 20, 2026
Why MSO Valuations Are Outperforming Despite Revenue Headwinds
In a year where most cannabis operators are reporting flat to negative revenue growth, the sector’s leading multi-state operators have seen their valuations re-rate significantly higher. Curaleaf, Trulieve, and Green Thumb have all outperformed the benchmark cannabis equity indices by wide margins. The divergence has caught many retail investors off guard, but the logic is actually quite straightforward for those watching the underlying fundamentals.
The Margin Story Is More Compelling Than the Revenue Story
Revenue growth was the dominant narrative for cannabis equities from 2019 through 2022. Operators were spending aggressively to build out infrastructure, acquire licenses, and capture market share in anticipation of federal legalization. That era is effectively over. Today’s market is rewarding operational excellence—getting more profit per dollar of revenue—rather than pure growth at any cost.
Green Thumb Industries recently reported an adjusted EBITDA margin of 28%, an impressive figure for the industry that reflects aggressive cost optimization across its portfolio of controlled subsidiaries. Trulieve has achieved similar metrics in its core Florida market, where vertical integration and geographic concentration have allowed it to extract margins that pure-play operators in competitive markets cannot match.
The Federal Catalyst Premium
Beyond operational improvements, institutional investors are increasingly pricing in a federal reclassification probability. While rescheduling from Schedule I to Schedule III won’t solve the core banking and 280E problems overnight, it removes a significant overhang that has kept institutional capital on the sidelines.
MajorMSOs like Verano and Canopy Growth are trading at multiples that suggest meaningful federal reform is already priced in—which means the risk-reward for new entrants has become less attractive at current levels.
What This Means for Portfolio Construction
For investors building positions in the cannabis space today, the calculus has shifted. Pure-play operators with high debt loads and questionable path to profitability deserve the discount they trade at. Quality names with demonstrated margin expansion—particularly those operating in limited-license states like Tilray’s Canadian operations—deserve premium valuations.
The sector rotation from growth-at-any-cost to quality-focused investing is a normal maturation pattern for emerging industries. Cannabis is simply following the script that tobacco, alcohol, and pharmaceutical sectors all followed in their early days of public market participation.
Sources
- Bloomberg Intelligence — MSO valuation metrics and sector analysis
- SEC EDGAR — Operator quarterly filings and earnings transcripts
Track cannabis stocks with the Weedstock Real-Time Tracker